Cargando…

Bifunctional ligand design for modulating mutant p53 aggregation in cancer

Protein misfolding and aggregation contributes to the development of a wide range of diseases. In cancer, over 50% of diagnoses are attributed to p53 malfunction due to missense mutations, many of which result in protein misfolding and accelerated aggregation. p53 mutations also frequently result in...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Jessica J., Blanchet, Anaïs, Orvain, Christophe, Nouchikian, Lucienne, Reviriot, Yasmin, Clarke, Ryan M., Martelino, Diego, Wilson, Derek, Gaiddon, Christian, Storr, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Royal Society of Chemistry 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006507/
https://www.ncbi.nlm.nih.gov/pubmed/32055386
http://dx.doi.org/10.1039/c9sc04151f
_version_ 1783495158677897216
author Miller, Jessica J.
Blanchet, Anaïs
Orvain, Christophe
Nouchikian, Lucienne
Reviriot, Yasmin
Clarke, Ryan M.
Martelino, Diego
Wilson, Derek
Gaiddon, Christian
Storr, Tim
author_facet Miller, Jessica J.
Blanchet, Anaïs
Orvain, Christophe
Nouchikian, Lucienne
Reviriot, Yasmin
Clarke, Ryan M.
Martelino, Diego
Wilson, Derek
Gaiddon, Christian
Storr, Tim
author_sort Miller, Jessica J.
collection PubMed
description Protein misfolding and aggregation contributes to the development of a wide range of diseases. In cancer, over 50% of diagnoses are attributed to p53 malfunction due to missense mutations, many of which result in protein misfolding and accelerated aggregation. p53 mutations also frequently result in alteration or loss of zinc at the DNA-binding site, which increases aggregation via nucleation with zinc-bound p53. Herein, we designed two novel bifunctional ligands, L(I) and L(H), to modulate mutant p53 aggregation and restore zinc binding using a metallochaperone approach. Interestingly, only the incorporation of iodine function in L(I) resulted in modulation of mutant p53 aggregation, both in recombinant and cellular environments. Native mass spectrometry shows a protein–ligand interaction for L(I), as opposed to L(H), which is hypothesized to lead to the distinct difference in the p53 aggregation profile for the two ligands. Incorporation of a di-2-picolylamine binding unit into the ligand design provided efficient intracellular zinc uptake, resulting in metallochaperone capability for both L(I) and L(H). The ability of L(I) to reduce mutant p53 aggregation results in increased restoration of p53 transcriptional function and mediates both caspase-dependent and -independent cell death pathways. We further demonstrate that L(I) exhibits minimal toxicity in non-cancerous organoids, and that it is well tolerated in mice. These results demonstrate that iodination of our ligand framework restores p53 function by interacting with and inhibiting mutant p53 aggregation and highlights L(I) as a suitable candidate for comprehensive in vivo anticancer preclinical evaluations.
format Online
Article
Text
id pubmed-7006507
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-70065072020-02-13 Bifunctional ligand design for modulating mutant p53 aggregation in cancer Miller, Jessica J. Blanchet, Anaïs Orvain, Christophe Nouchikian, Lucienne Reviriot, Yasmin Clarke, Ryan M. Martelino, Diego Wilson, Derek Gaiddon, Christian Storr, Tim Chem Sci Chemistry Protein misfolding and aggregation contributes to the development of a wide range of diseases. In cancer, over 50% of diagnoses are attributed to p53 malfunction due to missense mutations, many of which result in protein misfolding and accelerated aggregation. p53 mutations also frequently result in alteration or loss of zinc at the DNA-binding site, which increases aggregation via nucleation with zinc-bound p53. Herein, we designed two novel bifunctional ligands, L(I) and L(H), to modulate mutant p53 aggregation and restore zinc binding using a metallochaperone approach. Interestingly, only the incorporation of iodine function in L(I) resulted in modulation of mutant p53 aggregation, both in recombinant and cellular environments. Native mass spectrometry shows a protein–ligand interaction for L(I), as opposed to L(H), which is hypothesized to lead to the distinct difference in the p53 aggregation profile for the two ligands. Incorporation of a di-2-picolylamine binding unit into the ligand design provided efficient intracellular zinc uptake, resulting in metallochaperone capability for both L(I) and L(H). The ability of L(I) to reduce mutant p53 aggregation results in increased restoration of p53 transcriptional function and mediates both caspase-dependent and -independent cell death pathways. We further demonstrate that L(I) exhibits minimal toxicity in non-cancerous organoids, and that it is well tolerated in mice. These results demonstrate that iodination of our ligand framework restores p53 function by interacting with and inhibiting mutant p53 aggregation and highlights L(I) as a suitable candidate for comprehensive in vivo anticancer preclinical evaluations. Royal Society of Chemistry 2019-10-07 /pmc/articles/PMC7006507/ /pubmed/32055386 http://dx.doi.org/10.1039/c9sc04151f Text en This journal is © The Royal Society of Chemistry 2019 http://creativecommons.org/licenses/by-nc/3.0/ This article is freely available. This article is licensed under a Creative Commons Attribution Non Commercial 3.0 Unported Licence (CC BY-NC 3.0)
spellingShingle Chemistry
Miller, Jessica J.
Blanchet, Anaïs
Orvain, Christophe
Nouchikian, Lucienne
Reviriot, Yasmin
Clarke, Ryan M.
Martelino, Diego
Wilson, Derek
Gaiddon, Christian
Storr, Tim
Bifunctional ligand design for modulating mutant p53 aggregation in cancer
title Bifunctional ligand design for modulating mutant p53 aggregation in cancer
title_full Bifunctional ligand design for modulating mutant p53 aggregation in cancer
title_fullStr Bifunctional ligand design for modulating mutant p53 aggregation in cancer
title_full_unstemmed Bifunctional ligand design for modulating mutant p53 aggregation in cancer
title_short Bifunctional ligand design for modulating mutant p53 aggregation in cancer
title_sort bifunctional ligand design for modulating mutant p53 aggregation in cancer
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006507/
https://www.ncbi.nlm.nih.gov/pubmed/32055386
http://dx.doi.org/10.1039/c9sc04151f
work_keys_str_mv AT millerjessicaj bifunctionalliganddesignformodulatingmutantp53aggregationincancer
AT blanchetanais bifunctionalliganddesignformodulatingmutantp53aggregationincancer
AT orvainchristophe bifunctionalliganddesignformodulatingmutantp53aggregationincancer
AT nouchikianlucienne bifunctionalliganddesignformodulatingmutantp53aggregationincancer
AT reviriotyasmin bifunctionalliganddesignformodulatingmutantp53aggregationincancer
AT clarkeryanm bifunctionalliganddesignformodulatingmutantp53aggregationincancer
AT martelinodiego bifunctionalliganddesignformodulatingmutantp53aggregationincancer
AT wilsonderek bifunctionalliganddesignformodulatingmutantp53aggregationincancer
AT gaiddonchristian bifunctionalliganddesignformodulatingmutantp53aggregationincancer
AT storrtim bifunctionalliganddesignformodulatingmutantp53aggregationincancer